DelveInsight’s “Beta Thalassemia Pipeline Insight 2025” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Beta Thalassemia pipeline landscape. It covers the Beta Thalassemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Beta Thalassemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Beta Thalassemia Pipeline? Click here to explore the therapies and trials making headlines @ Beta Thalassemia Pipeline Outlook Report
Key Takeaways from the Beta Thalassemia Pipeline Report
Want to know which companies are leading innovation in Beta Thalassemia? Dive into the full pipeline insights @ Beta Thalassemia Clinical Trials Assessment
The Beta Thalassemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Beta Thalassemia Pipeline Report also highlights the unmet needs with respect to the Beta Thalassemia.
Beta Thalassemia Overview
Beta thalassemia is an inherited blood disorder that limits your body’s ability to make beta-globin. Beta-globin is an important protein needed to make hemoglobin and red blood cells. Beta thalassemia can cause the patient to experience anemia symptoms. There are several types of thalassemia. The types include beta thalassemia major, beta thalassemia intermedia and beta thalassemia minor. The signs and symptoms you have depend on the type and severity of your condition. Thalassemia signs and symptoms may include fatigue, weakness, pale or yellowish skin, facial bone deformities, slow growth, abdominal swelling, and dark urine.
Beta Thalassemia Emerging Drugs Profile
CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from β-thalassemia and sickle cell disease. The drug is in Phase I/II clinical evaluation for the treatment of β-thalassemia. CTX001 has been designated an orphan drug in the U.S. and Europe, and given fast track, rare pediatric disease, and regenerative medicine advanced therapy designations in the U.S. for SCD and transfusion-dependent Beta thalassemia (B-thal) (TDT).
VIT-2763 is an orally administered small molecule developed by Vifor Pharma. Intended for daily administration, VIT-2763 has the potential for treating diseases with impaired iron metabolism. Ferroportin is an iron transporter that plays a key role in regulating iron uptake and distribution in the body and thus in controlling iron levels in the blood. At the molecular level, VIT-2763 binds to ferroportin and blocks it to prevent excessive iron release into the blood. Pre-clinical evidence serving as the basis for the clinical development of VIT-2763 revolves around its efficacy for reducing elevated blood and tissue iron levels and for restricting iron uptake in patients suffering from conditions in which iron metabolism is altered. Vamifeport is currently in phase II development for beta-thalassemia, an inherited rare blood disorder that reduces the production of functional haemoglobin in red blood cells, which can lead to a lack of oxygen in many parts of the body and potentially cause anaemia.
Emeramide is an antioxidant heavy metal chelator. It prevents methylmercury-induced glutathione (GSH) loss, and cytotoxicity to, isolated mouse aortic endothelial cells when used at a concentration of 50 µM. Emeramide is a lipophilic, di-thiol antioxidant, anti-viral, and metal chelator. Orphan Drug Designations were received for the treatment of mercury toxicity in the EU and US. Pre-clinical safety studies, a Phase I trial, and four Phase II trials have been performed targeting multiple indications. Currently the drug is in phase II for the treatment of beta-thalassaemia.
If you’re tracking ongoing Beta Thalassemia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Beta Thalassemia Treatment Drugs
The Beta Thalassemia Pipeline report provides insights into:-
Beta Thalassemia Companies
CRISPR Therapeutics, CSL Vifor, Beam Therapeutics, EmeraMed, Fulcrum Therapeutics, Editas Medicine, EdiGene Inc, Silence Therapeutics, Phoenicia Biosciences, Shanghai BDgene, Disc Medicine and others.
Beta Thalassemia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
Beta Thalassemia Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Beta Thalassemia Pipeline Report covers it all – check it out now @ Beta Thalassemia Market Drivers and Barriers, and Future Perspectives
Scope of the Beta Thalassemia Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the Beta Thalassemia Treatment landscape in this detailed analysis @ Beta Thalassemia Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/beta-thalassemia-pipeline-insight
